TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26099756

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Continuous femoral nerve block (CFNB)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Combination of CFNB and ITM
Number of subjects: 81
Study: 22746542

Group type: EXPERIMENTAL
Intervention: Artichoke leaf extract (ALE) supplementation (250 mg, 2 b.i.d.)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 21232162

Group type: EXPERIMENTAL
Intervention: Online cognitive behavioural therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Online attention control placebo
Number of subjects: 0
Study: 19028952

Group type: EXPERIMENTAL
Intervention: 35 ml placebo gel
Number of subjects: 77

Group type: COMPARATOR
Intervention: 8 g placebo rectal suppositories
Number of subjects: 77
Study: 16855180

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 5145
Study: 12556780

Group type: EXPERIMENTAL
Intervention: Metal stent
Number of subjects: 118

Group type: COMPARATOR
Intervention: Plastic stent
Number of subjects: 118
Study: 10671393

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 8848990

Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study: 1593410

Group type: EXPERIMENTAL
Intervention: Meclofenamate (100 mg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Aspirin (500 mg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 6146164

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2 mg)
Number of subjects: 11
Study: 30078111

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) + D-cycloserine (DCS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) + Placebo
Number of subjects: 24
Study: 29970184

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Voglibose
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26727682

Group type: COMPARATOR
Intervention: Standard of Care (SOC) using pillows
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patient Positioning System (PPS)
Number of subjects: 60
Study: 24602520

Group type: EXPERIMENTAL
Intervention: ART plus LED sealants
Number of subjects: 405

Group type: COMPARATOR
Intervention: Resin-composite sealants
Number of subjects: 405

Group type: COMPARATOR
Intervention: Glass-carbomer sealants
Number of subjects: 405

Group type: COMPARATOR
Intervention: Conventional ART sealants
Number of subjects: 405

Group type: COMPARATOR
Intervention: Free smooth surfaces (all groups)
Number of subjects: 405
Study: 22783709

Group type: EXPERIMENTAL
Intervention: Metamizol 1 g three times daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg twice daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (NaCl)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g three times daily
Number of subjects: 120
Study: 20831534

Group type: EXPERIMENTAL
Intervention: Naloxone therapy
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Naloxone administered parenterally by intermittent or continuous infusions
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Infusion route of naloxone
Number of subjects: 1054
Study: 17506732

Group type: EXPERIMENTAL
Intervention: Morphine PCA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tramadol PCA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Codeine phosphate 60 mg IM
Number of subjects: 60
Study: 16225538

Group type: EXPERIMENTAL
Intervention: Standard circumcision procedure
Number of subjects: 479
Study: 12052801

Group type: EXPERIMENTAL
Intervention: Probiotics (yeast: Saccharomyces boulardii)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Probiotics (lactobacilli)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combined probiotics
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9866849

Group type: EXPERIMENTAL
Intervention: Thalassemia patients
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study: 8721892

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 2709305

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 332319

Group type: EXPERIMENTAL
Intervention: DTIC alone
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: methyl‐CCNU alone
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: DTIC plus methyl‐CCNU
Number of subjects: 415

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 415

Group type: COMPARATOR
Intervention: Responders
Number of subjects: 415

Group type: COMPARATOR
Intervention: DTIC
Number of subjects: 415

Group type: COMPARATOR
Intervention: methyl‐CCNU
Number of subjects: 415

Group type: COMPARATOR
Intervention: Combination DTIC plus methyl‐CCNU
Number of subjects: 415

Group type: COMPARATOR
Intervention: Favorable characteristics
Number of subjects: 415

Group type: COMPARATOR
Intervention: Unfavorable characteristics
Number of subjects: 415
Study: 6262148

Group type: EXPERIMENTAL
Intervention: Inactivated polio vaccine (IPV) combined with concentrated diphtheria and tetanus toxoid, administered in one or two injections at an interval of 6 months.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactivated polio vaccine C (higher concentration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral polio vaccine (OPV), 4 doses in 15 months (control group)
Number of subjects: 0
Study: 30835956

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of autologous adipose-derived mesenchymal stem cells (AD-MSCs)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 24
Study: 29138794

Group type: EXPERIMENTAL
Intervention: Clinical evaluation plus noninvasive testing (CCTA or stress test)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Clinical evaluation alone
Number of subjects: 1000
Study: 27018862

Group type: EXPERIMENTAL
Intervention: Low intensity lower limb cycling for 30 minutes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rest control condition for 30 minutes
Number of subjects: 12
Study: 25135262

Group type: EXPERIMENTAL
Intervention: Fumaric acid 5% cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triamcinolone 0.1% cream
Number of subjects: 0
Study: 21571394

Group type: EXPERIMENTAL
Intervention: Balicatib
Number of subjects: 709

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709

Group type: COMPARATOR
Intervention: Lowest balicatib dose
Number of subjects: 709
Study: 19053988

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 886

Group type: COMPARATOR
Intervention: Desloratadine 5 mg
Number of subjects: 886
Study: 17197313

Group type: EXPERIMENTAL
Intervention: Subvastus approach
Number of subjects: 20

Group type: COMPARATOR
Intervention: Midvastus approach
Number of subjects: 20
Study: 15681524

Group type: EXPERIMENTAL
Intervention: Radiation plus immediate androgen suppression (LHRH agonist)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Radiation alone with hormonal manipulation at time of relapse
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Radiation therapy and immediate hormonal manipulation
Number of subjects: 173
Study: 12017317

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 10360303

Group type: EXPERIMENTAL
Intervention: Cataract extraction and lens implantation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cataract extraction, lens implantation, and trabeculectomy
Number of subjects: 35
Study: 7813375

Group type: EXPERIMENTAL
Intervention: Surgical local excision
Number of subjects: 10
Study: 2529799

Group type: EXPERIMENTAL
Intervention: Loratadine 5 mg plus pseudoephedrine 120 mg
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 3094

Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 23

Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 23
Study: 31403958

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise program (MAE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Home exercise program (HEP)
Number of subjects: 40
Study: 28403018

Group type: EXPERIMENTAL
Intervention: Methylatropine (500 μg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 60
Study: 25970942

Group type: EXPERIMENTAL
Intervention: Occupational chronic stress exposure (OCS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Maladaptive cardiovascular response (MCVR)
Number of subjects: 60
Study: 23919595

Group type: EXPERIMENTAL
Intervention: Buprenorphine implants (BI)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo implants (PI)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine/naloxone tablets (BNX)
Number of subjects: 114
Study: 21900185

Group type: EXPERIMENTAL
Intervention: Positive cTnT at baseline
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Troponin conversion (from negative to detectable)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Baseline cTnT levels
Number of subjects: 288
Study: 19226191

Group type: EXPERIMENTAL
Intervention: Prostacyclin (epoprostenol, Flolan) at a dose of 0.5 ng/kg/min
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 17382651

Group type: EXPERIMENTAL
Intervention: Cryolife O'Brien stentless valve
Number of subjects: 78

Group type: COMPARATOR
Intervention: Toronto stentless valve
Number of subjects: 78
Study: 15321031

Group type: EXPERIMENTAL
Intervention: Sol to gel systems
Number of subjects: 15

Group type: COMPARATOR
Intervention: Marketed eye drops
Number of subjects: 15
Study: 10867450

Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg, 40 mg t.i.d.)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 9292454

Group type: EXPERIMENTAL
Intervention: DDD mode (normal increase in heart rate)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DOO‐Rest (HR fixed at resting value)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DOO‐Ex (HR fixed at peak exercise rate)
Number of subjects: 10
Study: 8243374

Group type: EXPERIMENTAL
Intervention: Felbamate (FBM)
Number of subjects: 73
Study: 3517076

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination therapy (pindolol 15 mg + hydrochlorothiazide 50 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pindolol 15 mg
Number of subjects: 24
Study: 30803532

Group type: EXPERIMENTAL
Intervention: 3% tetracaine plus 0.05% oxymetazoline (Kovanaze) nasal spray and mock infiltration
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mock nasal spray and 2% lidocaine with 1:100,000 epinephrine infiltration
Number of subjects: 50
Study: 28421628

Group type: EXPERIMENTAL
Intervention: Iodixanol (n=110)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Iohexol (n=110)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 220

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 220
Study: 25550228

Group type: EXPERIMENTAL
Intervention: Methylthioninium (MT) 138 mg/day
Number of subjects: 321

Group type: COMPARATOR
Intervention: Methylthioninium (MT) 69 mg/day and 228 mg/day
Number of subjects: 321
Study: 23451070

Group type: EXPERIMENTAL
Intervention: PCV7 in neonatal schedule (0-1-2 months)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: PCV7 in infant schedule (1-2-3 months)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control group (no PCV7)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: PPV at age 9 months
Number of subjects: 318
Study: 20888912

Group type: EXPERIMENTAL
Intervention: Early rapid corticosteroid reduction to 10 mg/day seven days post-transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard corticosteroid therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early rapid corticosteroid reduction
Number of subjects: 0
Study: 17520253

Group type: EXPERIMENTAL
Intervention: S-1 administered orally twice daily after meals at a dose of 80, 100, or 120 mg/day for body surface areas (BSAs) of less than 1.25 m(2), between 1.25 m(2) and less than 1.5, or 1.5 m(2) or greater, respectively, for 28 consecutive days, followed by a 14-day rest
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 40
Study: 16202394

Group type: EXPERIMENTAL
Intervention: Markers from the Canadian study (8 markers)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Supernormal controls
Number of subjects: 450
Study: 12936917

Group type: COMPARATOR
Intervention: Butter-enriched diet (low in trans FAs, 2.6 g trans FAs/100 g fat)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Semiliquid margarine (0.6 g trans FAs/100 g fat)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Soft margarine (9.4 g trans FAs/100 g fat)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Shortening (13.6 g trans FAs/100 g fat)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Stick margarine (26.1 g trans FAs/100 g fat)
Number of subjects: 36
Study: 10541929

Group type: EXPERIMENTAL
Intervention: Strength training (12 weeks, 3 days/week, four lower-body exercises)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2
Study: 9345420

Group type: EXPERIMENTAL
Intervention: 4.5 MIU recombinant human interferon alfa-2a (Roferon-A) given thrice weekly for 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 9.0 MIU recombinant human interferon alfa-2a (Roferon-A) given thrice weekly for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo given thrice weekly for 6 months
Number of subjects: 0
Study: 2052380

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Caffeine with acetaminophen (2 combinations)
Number of subjects: 53
Study: 6609270

Group type: EXPERIMENTAL
Intervention: New cuprophan hollow fiber dialyzers
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Formalin-fixed new dialyzers
Number of subjects: 11

Group type: COMPARATOR
Intervention: Re-used dialyzers
Number of subjects: 11
Study: 31032629

Group type: EXPERIMENTAL
Intervention: Group A (n=117): systematic discharge assessment with targeted advice
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Group B (n=116): motivational conversation and home visit
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control group (n=116)
Number of subjects: 349
Study: 27542725

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS applied to the left PMC prior to SRTT training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied to the left PMC prior to SRTT training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham tDCS applied to the left PMC prior to SRTT training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS applied during SRTT training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied during SRTT training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham tDCS applied during SRTT training
Number of subjects: 36
Study: 25772587

Group type: EXPERIMENTAL
Intervention: Walking exercise program, three times a week for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 0
Study: 25451894

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (standardized wound care)
Number of subjects: 38
Study: 22676466

Group type: EXPERIMENTAL
Intervention: Asha-Life intervention engaging with an HIV-trained village woman, Asha
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 68
Study: 21290835

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Medication and Acupuncture
Number of subjects: 131
Study: 17541116

Group type: EXPERIMENTAL
Intervention: fast, left frontal rTMS given three times a week over 4-6 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: sham treatment
Number of subjects: 29
Study: 15767642

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Combination (Anastrozole + Tamoxifen)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Tamoxifen (Control)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Anastrozole (Control)
Number of subjects: 330
Study: 11952187

Group type: EXPERIMENTAL
Intervention: Applied relaxation and self‐control desensitization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of applied relaxation, self‐control desensitization, and cognitive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal treatment (suggested addition)
Number of subjects: 0
Study: 9447851

Group type: EXPERIMENTAL
Intervention: Fentanyl at 3 ng/ml
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Fentanyl at 10 ng/ml
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Fentanyl (various concentrations)
Number of subjects: 92
Study: 7880699

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg kg‐1 (groups 1, 3, 5)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg kg‐1 (groups 2, 4, 6)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Neostigmine antagonism at PTC 0 (group 1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Edrophonium (groups 2, 4, 6)
Number of subjects: 72
Study: 2000827

Group type: EXPERIMENTAL
Intervention: dl‐alpha‐tocopherol 440 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: dl‐alpha‐tocopherol 880 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: dl‐alpha‐tocopherol 1320 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic administration of dl‐alpha‐tocopherol (440, 880, or 1320 mg/d for 28 d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinuation of treatment after day 28
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 0
Study: 6362322

Group type: EXPERIMENTAL
Intervention: Continuous intracutaneous Dexon 6
Number of subjects: 57

Group type: COMPARATOR
Intervention: Single knots of silk
Number of subjects: 57
Study: 30569798

Group type: EXPERIMENTAL
Intervention: Preconditioning session (warm-up followed by small-sided games, accelerations and 2 x 50-m maximal sprints)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Preconditioning session (Experimental)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no pre-loading session)
Number of subjects: 14
Study: 30662575

Group type: EXPERIMENTAL
Intervention: Four-channel FES group (n = 18)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dual-channel FES group (n = 15)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo group (n = 15)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Four-channel FES group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dual-channel FES group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 48
Study: 25677920

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg daily for 48 hours)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 22354336

Group type: EXPERIMENTAL
Intervention: Pre‐recorded video tutorial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Student self‐video
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 0
Study: 21272283

Group type: EXPERIMENTAL
Intervention: Training to read during rapid serial visual presentation (RSVP) (n = 20)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Training to optimize reading eye movements (SM, sensomotoric training) (n = 16)
Number of subjects: 36
Study: 20029518

Group type: EXPERIMENTAL
Intervention: Slow postmeal walking for 15 min (W15)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Slow postmeal walking for 40 min (W40)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (seated)
Number of subjects: 14
Study: 16483435

Group type: EXPERIMENTAL
Intervention: Preoperative intravenous ampiclox and vitamin B complex
Number of subjects: 278

Group type: COMPARATOR
Intervention: Vitamin B complex (placebo)
Number of subjects: 278
Study: 15516665

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 1453

Group type: EXPERIMENTAL
Intervention: Ex-smokers
Number of subjects: 1453

Group type: EXPERIMENTAL
Intervention: Current smokers (up to 14 cigarettes per day)
Number of subjects: 1453

Group type: EXPERIMENTAL
Intervention: Cumulative smoking
Number of subjects: 1453
Study: 10935688

Group type: EXPERIMENTAL
Intervention: Ritonavir (200 mg, four doses) with triazolam (0.125 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritonavir (200 mg, four doses) with zolpidem (5.0 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with triazolam (0.125 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with zolpidem (5.0 mg)
Number of subjects: 0
Study: 8848989

Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Transdermal clonidine weekly
Number of subjects: 24
Study: 1335403

Group type: EXPERIMENTAL
Intervention: Acute altitude challenge (3450 m)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acute exposure to mild hypoxia (14.5% oxygen)
Number of subjects: 10
Study: 6366560

Group type: EXPERIMENTAL
Intervention: Methylprednisolone alternated with chlorambucil every other month for six months
Number of subjects: 67

Group type: COMPARATOR
Intervention: Symptomatic treatment only (Control)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (Symptomatic treatment only)
Number of subjects: 67